Neovacs S.A. (EPA:ALNEV)

Market Cap	6.21K
Revenue (ttm)	433.94K
Net Income (ttm)	-32.91M
Shares Out	2.07M
EPS (ttm)	-188.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,440,055
Average Volume	42,381,239
Open	0.0030
Previous Close	0.0030
Day's Range	0.0028 - 0.0034
52-Week Range	0.0003 - 442.0000
Beta	-136.92
RSI	41.45
Earnings Date	Jun 4, 2025

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.